Biocon Limited
₹345-1.03%Apr 13, 3:45 PM IST
BIOCON•Health Technology•Pharmaceuticals: Major
Current Price
₹345-1.03%
Apr 13, 3:45 PM ISTMarket Cap₹56,449.89 Cr
Market Cap₹56,449.89 Cr
Business Overview
Biocon Limited operates through 4 main business divisions including Generics, Biosimilars, Research Services, Novel Biologics.
Business Hierarchy Structure for Biocon Limited
- Biocon Limited
- Generics
- Active Pharmaceutical Ingredients (APIs)
- Statin APIs
- Immunosuppressant APIs
- Specialty Molecules
- Oncology-based Highly Potent APIs (HPAPIs)
- Peptides (GLP-1s)
- Generic Formulations
- Cardiology Formulations
- Oncology Formulations
- Immunology Formulations
- Autoimmune Indications Formulations
- Anti-Fungal Formulations
- Anti-Diabetic Formulations
- Anti-Cancer Formulations
- Immunosuppressants Formulations
- Multiple Sclerosis Treatment Formulations
- Oral Solid Dosage Formulations
- Sterile Injectables (under construction)
- Mycophenolate Sodium (MPS)
- Dabigatran capsules
- Rivaroxaban tablets
- Vigabatrin capsules
- Famotidine oral suspension
- Liothyronine Sodium tablets
- Posaconazole tablets
- Mycophenolic Acid tablets
- Tacrolimus capsules
- Sacubitril / Valsartan tablets
- Rosuvastatin tablets
- Everolimus tablets
- Dasatinib tablets
- Liraglutide (gVictoza® and gSaxenda®)
- Semaglutide (gOzempic®)
- Active Pharmaceutical Ingredients (APIs)
- Biosimilars
- Insulins
- Monoclonal Antibodies
- Conjugated Recombinant Proteins
- Biosimilar Assets
- bAflibercept (YESAFILI®)
- bUstekinumab
- bAspart
- bBevacizumab
- bPertuzumab
- bGlargine (Semglee®)
- bAdalimumab
- bTrastuzumab
- Research Services
- Discovery Services
- Novel Molecular Entities
- AI-enabled Drug Discovery Tools
- Development Services
- Cloning
- Cell Line Development
- CMC
- Preclinical and Clinical Research
- Clinical Research Support
- Safety Services
- Development Strategy and Advisory
- Manufacturing Services
- Small Molecule Chemical Synthesis
- Large Molecule Biomanufacturing
- Fermentation-based APIs
- Synthetic APIs
- Peptide API
- Injectable Facility
- Oral Solid Dosage Manufacturing
- Fill-finish Unit
- Specialty Chemicals
- Discovery Services
- Novel Biologics
- Itolizumab (ALZUMAb®)
- Bicara Therapeutics (BCA101)
- Generics